Gilead Sciences, Inc. vs Quantum Computing Inc — how do they compare? Gilead Sciences, Inc. trades at $136.75 (market cap $168.35B), while Quantum Computing Inc trades at $8.95 (market cap $2.03B). The key difference: Gilead Sciences, Inc. is far larger — about 82.9× Quantum Computing Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| GILD | QUBT | |
|---|---|---|
Market Cap | $168.35B | $2.03B |
Sector | Health | Technology |
52-Week High | $155.80 | $24.62 |
52-Week Low | $110.56 | $6.31 |
Enterprise Value | $191.42B | $1.09B |
Dividend Yield | 2.42% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Quantum Computing Inc. (QUBT) trades at $9.07, up 1.57% with bearish technical signals despite recent revenue growth. The company reported Q2 2026 revenue of $5.6 million, a significant increase from prior periods, though profitability remains challenged with negative margins. Analyst consensus is bullish with a $18.50 price target, while institutional interest grows with recent purchases by Amundi and Bank of New York Mellon.
QUBT presents high-risk, high-reward potential with strong revenue growth from photonics sales but faces execution risks and negative profitability. The stock's 75% buy rating from analysts suggests upside potential, though investors must weigh the speculative nature against substantial cash reserves and expanding manufacturing capabilities.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →